PL2441466T3 - Środek hamujący MIC-1 - Google Patents

Środek hamujący MIC-1

Info

Publication number
PL2441466T3
PL2441466T3 PL11183884T PL11183884T PL2441466T3 PL 2441466 T3 PL2441466 T3 PL 2441466T3 PL 11183884 T PL11183884 T PL 11183884T PL 11183884 T PL11183884 T PL 11183884T PL 2441466 T3 PL2441466 T3 PL 2441466T3
Authority
PL
Poland
Prior art keywords
mic
inhibiting agent
inhibiting
agent
Prior art date
Application number
PL11183884T
Other languages
English (en)
Inventor
Samuel Norbet Breit
Asne Rhoda Bauskin
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2441466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of PL2441466T3 publication Critical patent/PL2441466T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL11183884T 2004-04-13 2005-04-13 Środek hamujący MIC-1 PL2441466T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP11183884.3A EP2441466B1 (en) 2004-04-13 2005-04-13 MIC-1 inhibiting agent
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
PL2441466T3 true PL2441466T3 (pl) 2015-01-30

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15163748T PL2929891T3 (pl) 2004-04-13 2005-04-13 Sposób modulowania apetytu
PL11183884T PL2441466T3 (pl) 2004-04-13 2005-04-13 Środek hamujący MIC-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15163748T PL2929891T3 (pl) 2004-04-13 2005-04-13 Sposób modulowania apetytu

Country Status (12)

Country Link
US (6) US8192735B2 (pl)
EP (4) EP2441466B1 (pl)
JP (4) JP5448338B2 (pl)
CA (2) CA2905125C (pl)
CY (1) CY1115731T1 (pl)
DK (2) DK2441466T3 (pl)
ES (3) ES2788868T3 (pl)
HK (2) HK1168274A1 (pl)
PL (2) PL2929891T3 (pl)
PT (2) PT2441466E (pl)
SI (1) SI2441466T1 (pl)
WO (1) WO2005099746A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2441466T1 (sl) 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
AU2008286706B2 (en) * 2007-08-16 2014-03-06 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
CN102203619B (zh) 2008-10-31 2015-12-16 圣文森特医院悉尼有限公司 慢性肾病中的预测方法
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
WO2013148117A1 (en) * 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2014049087A1 (en) 2012-09-26 2014-04-03 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AU2013364133B2 (en) 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
RS59700B1 (sr) 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
JP6768527B2 (ja) * 2014-06-20 2020-10-14 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
EP3851445A1 (en) * 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
MD20170020A2 (ro) * 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US20170334971A1 (en) * 2014-12-22 2017-11-23 Novo Nordisk A/S Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
EA201890850A1 (ru) 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
EP3425392A4 (en) 2016-02-29 2020-02-05 Public University Corporation Yokohama City University METHOD FOR DETECTING CASTRATION-RESISTANT PROSTATE CANCER AND REAGENT REAGENT
US10174119B2 (en) 2016-03-31 2019-01-08 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
CA3045700A1 (en) * 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
WO2019048660A1 (en) 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
US11055575B2 (en) 2018-11-13 2021-07-06 CurieAI, Inc. Intelligent health monitoring
BR112022010227A2 (pt) 2019-11-26 2022-09-13 Yuhan Corp Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
CA3219685A1 (en) 2021-05-21 2022-11-24 Seyoung LIM Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
EP4351627A1 (en) 2021-05-21 2024-04-17 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
ES2300325T3 (es) * 2000-04-20 2008-06-16 St Vincent's Hospital Sydney Limited Ensayo diagnostico que implica la citoquina 1 inhibitoria de macrofagos (mc1).
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
SI2441466T1 (sl) 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
DK1844337T3 (da) * 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
EP2396025A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease

Also Published As

Publication number Publication date
CY1115731T1 (el) 2017-01-25
EP2774620A1 (en) 2014-09-10
EP1734986A1 (en) 2006-12-27
CA2905125C (en) 2017-02-07
EP2441466B1 (en) 2014-07-23
CA2561877C (en) 2017-03-14
US20110123454A1 (en) 2011-05-26
US20150183861A1 (en) 2015-07-02
ES2518865T3 (es) 2014-11-05
US20180346560A1 (en) 2018-12-06
US8946146B2 (en) 2015-02-03
PL2929891T3 (pl) 2020-08-24
WO2005099746A1 (en) 2005-10-27
JP5767667B2 (ja) 2015-08-19
US20090004181A1 (en) 2009-01-01
EP1734986B1 (en) 2015-11-11
US8192735B2 (en) 2012-06-05
SI2441466T1 (sl) 2015-01-30
EP2441466A1 (en) 2012-04-18
US20160289320A1 (en) 2016-10-06
HK1215932A1 (zh) 2016-09-30
ES2555956T3 (es) 2016-01-11
CA2905125A1 (en) 2005-10-27
JP5806275B2 (ja) 2015-11-10
DK2929891T3 (da) 2020-05-11
DK2441466T3 (da) 2014-10-27
EP2929891B1 (en) 2020-03-11
EP2929891A1 (en) 2015-10-14
CA2561877A1 (en) 2005-10-27
US20210340243A1 (en) 2021-11-04
JP5448338B2 (ja) 2014-03-19
HK1168274A1 (en) 2012-12-28
ES2788868T3 (es) 2020-10-23
JP2013209376A (ja) 2013-10-10
JP2014051511A (ja) 2014-03-20
JP2011190262A (ja) 2011-09-29
PT2929891T (pt) 2020-04-08
JP2007532586A (ja) 2007-11-15
EP1734986A4 (en) 2009-07-22
PT2441466E (pt) 2014-09-09

Similar Documents

Publication Publication Date Title
PT2441466E (pt) Agente de inibição de mic-1
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
IL178033A0 (en) Herbicide-safener combination
PT1811990T (pt) Meio contra demodicose
ZA200606546B (en) Herbicide-safener combination
ZA200600423B (en) MLV-Cosmetic
DE502004004685D1 (en) Giessmaschine
DE502005006813D1 (en) Common-rail-injektor
DE502004004917D1 (en) Multiaxialkomplex
DE502005004945D1 (en) Auto-splice-system
GB0400310D0 (en) Anti-incrustation agent
GB0415611D0 (en) Haemoease
PL368096A1 (pl) Środek zwilżająco-piorący
EP1712217A4 (en) WRINKLE MITIGATION AGENT
EP1712219A4 (en) AGENT DECREASING WRINKLES
AU2909P (en) DT23 Dianella tasmanica
IL165455A0 (en) Combination
GB0418486D0 (en) Dexx+ crum-buster
AU156212S (en) Numberplate
AU300772S (en) Keyhead
GB0427945D0 (en) Tumblechump
GB0425410D0 (en) Car-a-way
GB0403460D0 (en) Dog-one
GB0416075D0 (en) Beeda-loo
GB0422655D0 (en) Katkabin